Jefferies Lifts Rating on Medpace, Cites Biotech Funding Recovery and Limited Near-Term AI Threats
Jefferies raised its rating on Medpace to Buy, pointing to a 56% rebound in biotech funding in H2 2025, a conservative balance sheet at the company, and a lower near-term risk from artificial intelligence. The broker expects new contract bookings to pick up in the back half of 2026 into 2027 given Medpace’s typical four- to six-quarter lag from fun…